Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Change in Account Payables: 2010-2025

Historic Change in Account Payables for Heron Therapeutics (HRTX) over the last 12 years, with Sep 2025 value amounting to -$20,000.

  • Heron Therapeutics' Change in Account Payables rose 47.37% to -$20,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 78.04%. This contributed to the annual value of $8.5 million for FY2024, which is 56360.00% up from last year.
  • Latest data reveals that Heron Therapeutics reported Change in Account Payables of -$20,000 as of Q3 2025, which was up 93.24% from -$296,000 recorded in Q2 2025.
  • Heron Therapeutics' Change in Account Payables' 5-year high stood at $9.6 million during Q2 2021, with a 5-year trough of -$7.3 million in Q3 2022.
  • Its 3-year average for Change in Account Payables is $799,273, with a median of -$20,000 in 2025.
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Change in Account Payables was 545.40% (2024), while the steepest drop was 386.07% (2024).
  • Quarterly analysis of 5 years shows Heron Therapeutics' Change in Account Payables stood at -$2.1 million in 2021, then crashed by 59.56% to -$3.3 million in 2022, then surged by 141.54% to $1.4 million in 2023, then grew by 10.22% to $1.5 million in 2024, then surged by 47.37% to -$20,000 in 2025.
  • Its last three reported values are -$20,000 in Q3 2025, -$296,000 for Q2 2025, and $624,000 during Q1 2025.